Jane E Dematte D'Amico

Grants

Grants per year 2002 2004 2005 2006 2007 2008 2009 2011 2017 2023 2028

• 6 Active
• 46 Finished

Grants per year

Search results

• Active

  Prot #RIN‐PF‐302: An Open‐label Extension Study of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis

  Bemiss, B. (PD/PI) & Dematte D'Amico, J. E. (PD/PI)

  United Therapeutics Corporation

  8/18/23 → 8/18/26

  Project: Research project

• Prot #GB44496: A Two‐Cohort, Phase II, Multicenter, Randomized, Double‐Blind, Parallel‐Group, Placebo‐Controlled Study Evaluating the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patients

  Bemiss, B. (PD/PI) & Dematte D'Amico, J. E. (PD/PI)

  PPD Investigator Services, LLC, Genentech, Inc

  6/26/23 → 8/10/27

  Project: Research project

• Prot #1366-0031: A Phase II, Randomised, Placebo-controlled, Double-blind, Parallel-group, Efficacy and Safety Study of at Least 48 Weeks of Oral BI 685509 Treatment in Adults with Early Progressive Diffuse Cutaneous Systemic Sclerosis

  Dematte D'Amico, J. E. (PD/PI)

  Boehringer Ingelheim Pharmaceuticals, Inc.

  3/24/23 → 3/24/26

  Project: Research project

• Molecular Biomarkers To Guide Therapy In The Systemic Sclerosis-Associated Interstitial Lung Disease

  Misharin, A. (PD/PI) & Dematte D'Amico, J. E. (Co-PD/PI)

  AbbVie Inc.

  10/19/22 → 10/18/25

  Project: Research project

• Prot #RIN-PF-301: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis

  Bemiss, B. (PD/PI) & Dematte D'Amico, J. E. (PD/PI)

  United Therapeutics Corporation

  4/28/22 → 4/30/26

  Project: Research project

• Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype Prospective Outcomes (ILD-PRO) Registry

  Bemiss, B. (PD/PI), Dematte D'Amico, J. E. (PD/PI) & Dematte D'Amico, J. E. (PD/PI)

  Duke University, Boehringer Ingelheim Pharmaceuticals, Inc.

  8/21/20 → 8/21/28

  Project: Research project

• Finished

  Prot #FGCL-3019-091: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

  Dematte D'Amico, J. E. (PD/PI)

  Worldwide Clinical Trials, Inc., FibroGen, Inc.

  9/9/19 → 6/30/25

  Project: Research project

• Prot #1199-0324: Study of Pulmonary Rehabilitation In Nintedanib Treated Patients with IPF: Improvements in Activity, Exercise Endurance Time, and QoL

  Dematte D'Amico, J. E. (PD/PI) & Bhorade, S. M. (Other)

  Boehringer Ingelheim Pharmaceuticals, Inc.

  2/28/19 → 2/28/22

  Project: Research project

• Prot #1199.225: An Open-Label Extension Trial to Assess the Long Term Safety of Nintedanib in Patients with 'Systemic Sclerosis Associated Interstitial Lung Disease' (SSc-ILD)

  Dematte D'Amico, J. E. (PD/PI)

  Boehringer Ingelheim Pharmaceuticals, Inc.

  5/24/18 → 11/30/23

  Project: Research project

• Prot #ML30172: Scleroderma Lung Study III (SLS III): Combining the anti-fibrotic effects of pirfenidone (PFD) with mycophenolate (MMF) for treating scleroderma-related interstitial lung disease

  Dematte D'Amico, J. E. (PD/PI)

  University of California, Los Angeles, Genentech, Inc

  1/24/18 → 1/24/24

  Project: Research project

• Prot #IIS2017-10679: Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD using High Throughput Single-cell RNA-Seq

  Gottardi, C. J. (PD/PI), Bhorade, S. M. (Co-PD/PI), Dematte D'Amico, J. E. (Co-Investigator), Hinchcliff, M. E. (Co-Investigator) & Lam, A. P. (Other)

  Boehringer Ingelheim Pharmaceuticals, Inc.

  12/28/17 → 12/28/24

  Project: Research project

• Wnt-beta-catenin cross interactions in alveolar macrophages and epithelial cells in persistence of SSc-ILD

  Dematte D'Amico, J. E. (PD/PI), Dematte D'Amico, J. E. (PD/PI), Gottardi, C. J. (PD/PI), Gottardi, C. J. (PD/PI), Hinchcliff, M. E. (PD/PI), Hinchcliff, M. E. (PD/PI), Lam, A. P. (PD/PI), Lam, A. P. (PD/PI), Berdnikovs, S. (Co-Investigator), Berdnikovs, S. (Co-Investigator), Budinger, G. S. (Co-Investigator), Budinger, G. S. (Co-Investigator), Dematte D'Amico, J. E. (Co-Investigator), Dematte D'Amico, J. E. (Co-Investigator), Hinchcliff, M. E. (Co-Investigator), Misharin, A. (Co-Investigator) & Misharin, A. (Co-Investigator)

  National Heart, Lung, and Blood Institute

  12/22/17 → 11/30/24

  Project: Research project

• Prot #1199.247: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

  Dematte D'Amico, J. E. (PD/PI)

  Boehringer Ingelheim Pharmaceuticals, Inc.

  8/16/17 → 2/16/24

  Project: Research project

• Prot #EMR200017-014: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Efficacy and Safety of Abituzuma in Subjects with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

  Dematte D'Amico, J. E. (PD/PI)

  Quintiles, Inc., EMD Serono Research & Development Institute, Inc.

  9/12/16 → 9/12/19

  Project: Research project

• Prot #1199.214: A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’(SSc-ILD)

  Dematte D'Amico, J. E. (PD/PI)

  Boehringer Ingelheim Pharmaceuticals, Inc.

  2/11/16 → 11/30/21

  Project: Research project

• Prot #PSSc-001: An Open-Label, Randomized, Phase 2 Study of the Safety and Tolerability of Pirfenidone when Administered to Patients with Systemic Sclerosis−Related Interstitial Lung Disease; The LOTUSS Trial: An Open-Label, RandOmized, Phase 2 STUdy of t

  Dematte D'Amico, J. E. (PD/PI)

  InterMune, Inc.

  9/5/13 → 9/5/16

  Project: Research project

• Prot# ACE114622: A Two Part Study to Investigate the Safety, Tolerability, Pharmacokinetics and Parmacodynamics of GSK2586881 in Patients with Acute Lung Injury

  Wunderink, R. G. (PD/PI), Dematte D'Amico, J. E. (Co-PD/PI) & Weiss, C. H. (Co-PD/PI)

  GlaxoSmithKline LLC

  5/8/12 → 10/10/14

  Project: Research project

• Prot# AC-063B201: A Phase 2, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Inhaled Iloprost on Endurance Time During Cardiopulmonary Exercise Testing in Patients with Pulmonary Hypertension Secondary to Chroni

  Cuttica, M. J. (PD/PI), Dematte D'Amico, J. E. (Co-PD/PI), Kalhan, R. (Co-PD/PI), Rosenberg, S. R. (Co-PD/PI) & Shah, S. J. (Co-PD/PI)

  Actelion Ltd.

  3/19/12 → 3/19/15

  Project: Research project

• PKD11791: A Randomized, Double-blind, Placebo-Controlled Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of SAR279356 in Patients Hospitalized in Intensive Care Unit and on Mechanical Ventilation

  Wunderink, R. G. (PD/PI), Dematte D'Amico, J. E. (Co-PD/PI) & Prickett, M. (Co-PD/PI)

  Sanofi US Services Inc.

  10/27/11 → 10/27/14

  Project: Research project

• Prot#RIN-PH-403: A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated with Tyvaso (Treprostinil) Inhalation Solution

  Cuttica, M. J. (PD/PI), Dematte D'Amico, J. E. (Co-PD/PI) & Shah, S. J. (Co-PD/PI)

  United Therapeutics Corporation

  9/29/11 → 2/28/15

  Project: Research project

• (TERMINATED 05/01/2012) Prot# BA-I-H-0903: Randomized, Multi-Centre, Controlled Clinical Study on the Effect of the S.A.F.E. bt Therapy on Disease Severity and Inflammation in Mechanically-Ventilated Subjects due to Severe Sepsis

  Wunderink, R. G. (PD/PI), Cuttica, M. J. (Co-PD/PI), Dematte D'Amico, J. E. (Co-PD/PI), Ghossein, C. (Co-PD/PI) & Weiss, C. H. (Co-PD/PI)

  Theorem Clinical Research, SAFE bt, INC.

  6/10/11 → 6/10/14

  Project: Research project

• Prot#BSTE-0409: Rapid Evaluation of Acute Kidney Injury with NGAL in Acutely Ill Patients in the ICU (REAL-ICU)

  Wunderink, R. G. (PD/PI), Dematte D'Amico, J. E. (Co-PD/PI) & Weiss, C. H. (Co-PD/PI)

  Alere San Diego, Inc.

  4/20/11 → 4/19/14

  Project: Research project

• Prot# PAB05: Estimation of the Incidence of Ventilator-Associated Pneumonia Caused by Pseudomonas aeruginosa (VAP-Pa)

  Wunderink, R. G. (PD/PI), Dematte D'Amico, J. E. (Co-PD/PI) & Weiss, C. H. (Co-PD/PI)

  Clinical Financial Services, LLC, Sanofi Pasteur Limited

  3/21/11 → 3/21/14

  Project: Research project

• AGMT 02/10/11: CONFRONT PAH: CombinatiON up-FRON t Therapy for PAH-A Phase 4, Randomized, Multicenter Study of Inhaled Treprostinil in Treatment-naive Pulmonary Arterial Hypertension Patients Starting on Tadalafil

  Cuttica, M. J. (PD/PI), Dematte D'Amico, J. E. (Co-PD/PI) & Shah, S. J. (Co-PD/PI)

  United Therapeutics Corporation

  2/10/11 → 2/10/17

  Project: Research project

• Prot# AC-063A402: A Phase IIIb, Multicenter, Open-Label Study of Patients with Pulmonary Arterial Hypertension Treated with Iloprost (Inhalation) Evaluating Safety and Inhalation Times When Converting from Power Disc-6 to Power Disc-15 With the I-Neb AAD

  Dematte D'Amico, J. E. (PD/PI), Cuttica, M. J. (Co-PD/PI) & Shah, S. J. (Co-PD/PI)

  Paragon Biomedical, Inc., Actelion Ltd.

  5/14/09 → 5/14/12

  Project: Research project